Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TRVI 
Trevi Therapeutics Inc (TRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: TRVI (5-star) is a STRONG-BUY. BUY since 79 days. Simulated Profits (55.56%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20.6
1 Year Target Price $20.6
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 171.25% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.30B USD | Price to earnings Ratio - | 1Y Target Price 20.6 |
Price to earnings Ratio - | 1Y Target Price 20.6 | ||
Volume (30-day avg) 8 | Beta 0.84 | 52 Weeks Range 2.36 - 11.83 | Updated Date 11/5/2025 |
52 Weeks Range 2.36 - 11.83 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.1 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.83% | Return on Equity (TTM) -35.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 961192733 | Price to Sales(TTM) - |
Enterprise Value 961192733 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.92 | Shares Outstanding 121776855 | Shares Floating 90633642 |
Shares Outstanding 121776855 | Shares Floating 90633642 | ||
Percent Insiders 0.72 | Percent Institutions 94.75 |
Upturn AI SWOT
Trevi Therapeutics Inc
Company Overview
History and Background
Trevi Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic pruritus and other chronic conditions. Founded to address unmet needs in these areas.
Core Business Areas
- Nalbuphine ER Development: Developing Nalbuphine ER (Haduvio) for the treatment of pruritus (itch) associated with various conditions, including prurigo nodularis.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives. The organizational structure is typical of a clinical-stage biopharmaceutical company.
Top Products and Market Share
Key Offerings
- Haduvio (Nalbuphine ER): Haduvio is an extended-release oral formulation of nalbuphine. It has received FDA approval and is indicated for the treatment of pruritus associated with prurigo nodularis. The market for pruritus therapeutics is growing. Competitors include Regeneron (DUPIXENT) and other topical and systemic therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is focused on developing novel therapeutics for a variety of diseases. The pruritus market is growing, driven by an aging population and increasing prevalence of chronic conditions.
Positioning
Trevi Therapeutics is positioned as a company focused on addressing unmet needs in chronic pruritus. Their competitive advantage lies in their oral Nalbuphine ER formulation.
Total Addressable Market (TAM)
The TAM for pruritus therapeutics is estimated to be several billion dollars. Trevi Therapeutics is positioned to capture a portion of this market with Haduvio.
Upturn SWOT Analysis
Strengths
- FDA approved product (Haduvio)
- Oral formulation provides convenience
- Experienced management team
- Focused on unmet medical need
Weaknesses
- Reliance on a single product
- Commercialization risks
- Limited financial resources
- Market access challenges
Opportunities
- Expansion to other pruritus indications
- Partnerships with larger pharmaceutical companies
- Geographic expansion
- Pipeline development of new therapies
Threats
- Competition from existing and emerging therapies
- Regulatory risks
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- REGN
- SAN
- LLY
Competitive Landscape
Trevi Therapeutics faces competition from established pharmaceutical companies with approved therapies for pruritus. Their advantage lies in Haduvio, a targeted therapy that may offer improved efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's development stage. Growth is projected to accelerate with the commercial launch of Haduvio.
Future Projections: Future projections depend on the successful commercialization of Haduvio and pipeline development.
Recent Initiatives: Recent initiatives include commercial launch preparation and marketing efforts for Haduvio.
Summary
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for pruritus. They have a new product Haduvio, which addresses unmet needs in pruritus. Commercial execution is key to the company's success. The company faces challenges from larger competitors and regulatory risk but has significant opportunity for growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trevi Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2019-05-07 | Co-Founder, CEO, President, Interim Principal Financial Officer & Director Ms. Jennifer L. Good | ||
Sector Healthcare | Industry Biotechnology | Full time employees 33 | |
Full time employees 33 | |||
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.